The effect of clopidogrel on the rate of progression of MCI Lead Investigator: Alexander Pattison Institution : Eastern Virginia Medical School E-Mail : PattisAM@EVMS.EDU Proposal ID : 767 Proposal Description: Although the exact mechanism involved in A#946 amyloid production and Alzheimer?s Disease is not fully understood, platelets have been proposed as a possible source for both the amyloid precursor proteins and enzymes needed for this transformation (Catricala et al. 2012, Gowert et al. 2014). Recent evidence using transgenic AD mouse models suggests that clusterin acts as a stimulus for this process and that the use of the anti-platelet medication clopidogrel, which lowers plasma clusterin levels, may decrease both A#946 amyloid production and rates of dementia (Donner et al. 2016). If this result correlates to human subjects, clopidogrel could become a useful tool for reducing the overall risk of future Alzheimer?s Disease. Our study aims to use the NACC database to explore the effect of clopidogrel on the rate of progression of MCI in healthy controls and also the rate of progression of MCI to dementia stage. We plan to run a longitudinal comparative analysis between two groups of clopidogrel users vs. non-clopidogrel users based on rate and total decline of MMSE scores. We hope to see a decrease in rate of cognitive decline in clopidogrel users.